ELAB vs. ATHE, GHSI, GRTX, MBRX, AEZS, AKTX, MYNZ, ABVC, MNPR, and PPBT
Should you be buying Elevai Labs stock or one of its competitors? The main competitors of Elevai Labs include Alterity Therapeutics (ATHE), Guardion Health Sciences (GHSI), Galera Therapeutics (GRTX), Moleculin Biotech (MBRX), Aeterna Zentaris (AEZS), Akari Therapeutics (AKTX), Mainz Biomed (MYNZ), ABVC BioPharma (ABVC), Monopar Therapeutics (MNPR), and Purple Biotech (PPBT). These companies are all part of the "pharmaceutical preparations" industry.
Elevai Labs (NASDAQ:ELAB) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends, community ranking and analyst recommendations.
Alterity Therapeutics has a consensus target price of $7.00, indicating a potential upside of 178.88%. Given Alterity Therapeutics' higher probable upside, analysts clearly believe Alterity Therapeutics is more favorable than Elevai Labs.
22.2% of Elevai Labs shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Elevai Labs has higher earnings, but lower revenue than Alterity Therapeutics.
In the previous week, Elevai Labs had 3 more articles in the media than Alterity Therapeutics. MarketBeat recorded 4 mentions for Elevai Labs and 1 mentions for Alterity Therapeutics. Elevai Labs' average media sentiment score of 0.00 beat Alterity Therapeutics' score of -1.00 indicating that Elevai Labs is being referred to more favorably in the media.
Alterity Therapeutics received 3 more outperform votes than Elevai Labs when rated by MarketBeat users.
Summary
Elevai Labs and Alterity Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.
Get Elevai Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Elevai Labs Competitors List
Related Companies and Tools
